Induction of immune response to antigens expressed by recombinant adeno-associated virus

Patent Citations (13)

Non-Patent Literature (132)

• Restifo et.al.; Molecular Mechanisms Used by Tumors toEscape Immune Recognition: Immunogenetherapy and the Cell . . . Complex, 1993, Journal of Immunotherapy 14: 182-190.Applicant
• Ross et.al.; Gene Therapy in the United States: A Five-Year Status Report, 1996, Human Gene Therapy 7: 1781-1790.Applicant
• Yasutomi et.al.; A Vaccine-Elicited, Single viral Epitope-Specific Cytotoxic T . . . Simian Immunodeficiency Virus Challenge, 1995, Journal of Virology: 2279-2284.Applicant
• Monteil et.al.; Genetic Immunization of seronegative one-day-old piglets against pseudorabies . . . in piglets from immune dams, 1996, Elsevier:444-452.Applicant
• ERtl et.al.; Genetic Immunization, 1996, Viral Immunology, vol. 9: 1-9/.Applicant
• Khleif, et.al., “A Phase I Vaccine Trial with Peptides Relecting ras Oncogene Mutations of Solid Tumors,” Journal of Immunotherapy, vol. 22, No. 2 (Mar. 1999) 155-165.Applicant
• Abbas et al., Nature, vol. 383, 787-793, 1996.Applicant
• Ajello et al., “Adenovirus 5 DNA Sequences Present and RNA Sequence Transcribed in Transformed Human Embryo Kidney Cells (HEK-Ad-5 or 293)” Virol., 94:460-469 (1979).Applicant
• Akidis et al., “Epitope-specific T Cell Tolerance to Phospholipase A, in Bee Venom Immunotherapy and Recovery bu IL-2 and IL-15 in Vitro”, J. Clinic Inverstment, 18, 1676-1683, 1996.Applicant
• Anderson, “Human Gene Therapy,” Nature 392:25-30 (1998).Applicant
• Anderson and Young, “Quantitative Filter Hybridization, in Nucleic Acid Hybridization”, pp. 73-111, 1985.Applicant
• Attays et al., “Ham-2 corrects the antigen-processing defect in RMA-S cells,” Nature 355-647-649, 1992.Applicant
• Barr et al., “Efficient Catheter-mediated gene transfer into the heart using replication-defective adenovirus,” Gene Therapy, 1:51-58, 1994.Applicant
• Bauer et al., “Modulation of the Allergic Immune Response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v.1,” Clin. Exp. Immunol., 107:536-541., 1997.Applicant
• Berkner, “Development of Adenovirus Vectors for the Expression of Heterologous Genes,” BioTechn., 6: 616-629, 1988.Applicant
• Berns, “Parvoviridae and Their Replication” in Fundamental Virology, 2nd Edition, Fields and Knipe (eds.), pp. 817-837, Raven Press, New York, 1991.Applicant
• Berns and Bohenzky, “Adeno-Associated Viruses: An Update, ”Adv. Virus Res., 32: 243-306, 1987.Applicant
• Bett et al., “Packaging Capacity and Stability of Human Adenovirus Type 5 Vectors,” J. Virol., 67-5911-5921, 1993.Applicant
• Boshart, et al., “A Very Strong Enhancer is Located Upstream of an Immediate Early Gene of Human Cytomegalovirus,” Cell 41:521-530, 1985.Applicant
• Butler et al., “Herpes Simplex Virus Types 1 and 2 Completely Help Adenovirus-Associated Virus Replication,” J. Virol. 40, 241-47, 1981.Applicant
• Byrnes et al, “Immunological Instability of Persistent Adenovirus Vectors in the Brain: Peripheral Exposure to Vector Leads to Renewed Imflammation Reduced Gene Expression, and Demyelination,” J. Neuroscience 16: 3045-3055 (1996).Applicant
• Cao et al., “Vaccination with a multi-epitopic recombinant allergen induces specific immune deviation via T-cell energy,” Immunol, 90: 46-51, 1997.Applicant
• Capecchi, “High Efficiency Transformation by Direct Microinjection of DNA into Cultured Mammalian Cells,” Cell 22:479-488, 1980.Applicant
• Carter, “Adeno-associated virus vectors,” Current Opinion Biol., 3, 533-39, 1992.Applicant
• Carter, “Adeno-Associated Virus Helper Functions,” in CRC Handbook of Parvoviruses, Voll (P. Tijssen, ed.,) 533-39, 1990.Applicant
• Chamberlin et al., “New RNA Polymerase from Escherichia coli infected with Bacteriophage T7,” Nature 228:227, 1970.Applicant
• Chao, et al., “Sustained Expression of Human Factor VIII in Mice Using a Parvovirus-Based Vecotr,” Blood, vol. 95 No. 5, Mar. 1, 2000 1594-98.Applicant
• Chu and Sharp,“SV40 DNA transfection of cells in suspension analysis of the efficiency of transcription and translation of T-antigen,” Gene 13:197-202, 1981.Applicant
• Cole et al., “The EBV-Hybridoma Technique and its Application to Human Lung Cancer,” in Monoclonal Antibodies and Cancer Therapy, Alan R,. Liss, 77-96, 1985.Applicant
• Cole et al., “Generation of Human Monoclonal Antibodies Reactive with Cellular Antigens,” Proc., Natl. Acad. Sci., USA, 80, 2026-30, 1983.Applicant
• Colosi et al., Blood 86 No. Suppl. 1, 627a, 1995.Applicant
• Condon, DNA-based immunization by in vitro transfection of dendritic cells, Nature Med., 2, 1122-28, 1996.Applicant
• Conrad et al., “Safety of Single-does Administration of an Adeno-associated Virus (AAV)-CFTR Vector in the Primate Lung.” Gene Therapy., 3: 658-668 (1996).Applicant
• Davis et al., Basic Methods in Molecular Biology, Elsevier, 1986.Applicant
• Dijkema et al, Cloning and Expression of the Chromosomal Immune Interferon Gene of the rat, Embo J. 4, 761767, 1985.Applicant
• Doe et al., Induction of HIV1 envelope (gp 120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans, Eur. J. Immunol., 24:2369-2376, 1994.Applicant
• Edge et al., “Total Synthesis of a Human Leukocyte Interferon Gene,” Nature 292:756-61, 1981.Applicant
• Erickson et al., Hepatitis C. Virus-Specific, CTL, Responses in the Liver of Chimpanzees with Acute and Chronic Hepatitis C, J. Immunol., 151:4189-4199 (1993).Applicant
• Erlich (ed.), PCR Technology, Stockton Press (1989) (Title and Copyright Pages only).Applicant
• Falo Jr. et al., “Targeting antigen into the Phagocytic pathway in vivo induces protective tumour immunity,” Nature Med., 1, 649-53, 1995.Applicant
• Felgner et al., Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure, Proc. Natl. Acad. Sci. USA 84:7413-17, 1987.Applicant
• Fisher et al., “Recombinant adeno-associated virus for muscle directed gene therapy,” Nature Med., 3:306-312, 1997.Applicant
• Flotte et al., “Stable in vitro expression fo the cystic fibrosis transmembrance conductance regulator with an adeno-associated virus vector,” Proc. Natl. Acad. Sci. USA, 90:10613-16017, 1993.Applicant
• Geysen et al., “A Priori Delineation of a Peptide which Mimics a Discontinuous Antigenic Determinant,” Mol. Immunol., 23, 709-15, 1986.Applicant
• Geysen, et al., “Use of Peptide synthesis to probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid,” Proc. Natl. Acad. Sci. USA 81:3998-4002, 1984.Applicant
• Glover et al., (ed.,) DNA Cloning: A Practical Approach, vols. I & II, 2nd ed., Oxford, New York, IRL Press (1995) (Title and Copyright Pages Only).Applicant
• Golding, et al. Am. J. Topr. Med. Hyg. vol. 50(4) 33-40.Applicant
• Gorman et al., “The Rous srcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-medicated transfection,” Proc. Natl. Acad. Sci. USA, 79, 6777-81, 1982.Applicant
• Graham et al., “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,” J. Gen. Virol., 36, 59-72.Applicant
• Graham et al., “A new Technique for the Assay of Infectivity of Human Adenovirus Type 5,” J. Gen. Virol, 52: 456-467, 1973.Applicant
• Greenburg et al., Endocrine Soc., Jun. 9-11: Abstract 1206 (1993).Applicant
• Haj-Ahmad and Graham,“Development of a Helper-Independent Human Adenovirus Vector and Its Use in the Transfer of the Herpes Simplex Virus Thymidine Kinase Gene,” J. Virol. 57: 267-74, 1986.Applicant
• Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1988.Applicant
• Harris et al., “Molecular Basis for Heterogeneity of the Humans p53 Protein,” Mol Cell Biol., 6, 4650-56, 1986.Applicant
• Hergoz, Roland W., “Stable Gene Transfer and Expression of Human Blood Coagulation Factor IX after intramuscular Injection of Recombinant Adeno-Associated Virus,” Proc. Natl. Acad. Sci. USA, vol. 94, 5804-09, May , 1997.Applicant
• Hoyne et al., “Inhibition of T-cell Responses by Feeding Peptides Containing Major and Cryptic Epitopes; Studies with the der p1 allergen,” Immunol., 83, 190-95, 1994.Applicant
• Huber et al., “Retroviral-mediated gene therapy for the Treatment of Hepatocellular carcinoma: An innovative approach for cancer therapy,” Proc. Natl. Acad. Sci. USA 88:8039-43, 1991.Applicant
• Huse et al., “Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda,” Science 246, 1275-81, 1989.Applicant
• Janik et al., “Locations of Adenovirus Genes required for the Replication of Adenovirus-associated Virus,” Proc. Natl. Acad. Sci. USA 78: 1925-1929, 1981.Applicant
• Jay et al., “Chemical Synthesis of a Biologically Active Gene for Human Immune Interferon-y,” J. Biol. Chem., 259, 6311-17, 1984.Applicant
• Jooss et al., “Transduction of Dendritic Cells by DNA Viral Vectors Directs the Immune Response to Transgene Products in Muscle Fibers,” J. Virol. 72 (5):4212-4223 (1998).Applicant
• Kass-Eisler et al., “The impact of developmental stage, route of administration and the immune system on adenovirus-infected hepatocytes in vivo,” Gene Therapy, 1: 395-402 (1994).Applicant
• Karttunen et al., Detection of rare antigen-presenting cells by the lacZ T-cell activation assay suggests an expression cloning strategy for T-cell entigens, Proc. Natl. Acad. Sci. USA, 89, 6020-24, 1992.Applicant
• Kaplitt et al., “Viral Vectors for Gene Delivery and Expression in the CNS,” Methods: A Companion to Methods in Enzymology 10: 343-350 (1996).Applicant
• Kessler et al., Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein, Proc. Natl. Acad. Sci. UAS 24, vol. 93, 14082-87, 1996.Applicant
• Kim et al., “Use of the Human Elongation Factor 1a promoter as a versatile and efficient expression system.”, Gene 91, 217-223, 1990.Applicant
• Kim et al., “Quantitative Analysis of T Cell Activation,” J. Immunol., 156: 2737-42, 1996.Applicant
• Klein et al., “High-velocity microprojective for deliverying nucleic acids into living cells,” Nature 327: 70-73, 1987.Applicant
• Kohler and Milstein, “Continuous cultures of fused cells secreting antibody of predefined specificity.” Nature, 256, 495-97, 1975.Applicant
• Kotin, “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy.” Human Gene Ther. 5, 793-801, 1994.Applicant
• Kozbor et al., “The production of monoclonal antibodies from human lymphocytes,” Immunol. Today 4:72-79, 1983.Applicant
• Lang, In Principles of Animal Virology, Jokik (ed.) 255-57, Appleton-Centruy-Crofts, New York, 1980.Applicant
• Lebowski et al., Adeno-Associated Virus: a Vector System for Efficient Introduction and Integration of DNA into a Variety of Mammalian Cell Types, Mol. Cell. Biol., 8, 3988-96, 1988.Applicant
• Liu, et al., “Recombinant Adeno-Associated Virus Expressing Human Papillomavirus Type 16 E7 Peptide DNA Fused with Heat Shock Protein DNA as a Potential Vaccine for Cervical Cancer,” J. Virol. Mar., 2000, 2888-2894.Applicant
• Maniatis et al., “:Regulation of Inducible and Tissue Specific Gene Expression,” Science, 236, 1237-44, 1987.Applicant
• Manning, et al., “Genetic Immunization with Adeno-Associated Virus Vectors Expressing Herpes Simplex Virus Type 2 Glycoproteins B and D,” J. Virol. Oct., 1997, 7960-62.Applicant
• Mannino et al., “Liposome Mediated Gene Transfer,” BioTech., 6, 682-290, 1988.Applicant
• Marshall et al., Science, vol. 269, 1050-1055 (1995).Applicant
• Matusik et al., “Regulation of Prostatic Genes; role of androgens and zinc in gene expression,” Biochem and Cell Biol., 64, 601-07, 1986.Applicant
• McCarty et al., “Sequences Required for Coordinate Induction of Adeno-Associate Virus p19 and p 40 Promoters by Rep Protein,” J. Virol., 65, 2936-45, 1991.Applicant
• McKechnie et al., “Cross-reactive antigens in the pathogenesis of onchocerciasis,” Ann Trop. Med. Parasitol, 876, 649-652, 1993.Applicant
• McPherson et al., “Human Cytomegalovirus Completely Helps Adeno-Associated Virus Replication,” Virol, 147, 217-22, 1985.Applicant
• Mittereder, et al., “Evaluation of the Efficacy and Safety of In Vitro, Adenovirus-Mediated Transfer of the Human Cystic Fibrosis Transmembrance Conductance Regulator cDNA,” Human Gene Therapy, 5, 717-29, 1994.Applicant
• Mizuhima and Nagata, “pEF-BOS, a powerful mammalian expression vector,” Nuc. Acids. Res., 18, 5322, 1990.Applicant
• Mizuno et al., “Adeno-associated Virus Vector Containing the Herpes Simplex Virus Thymidine Kinase Gene Causes Complete Regression of Intracerebrally Implanted Human Gliomas in Mice, in Conjuction with Ganciclovir Administration,” Jpn. J. Cancer Res., 89: 76-80 (1998).Applicant
• Monaco, “A Molecular Model of MHC -restricted antigen processing,” Immunol. Today 13, 173-78, 1992.Applicant
• Muzyezka, “Use of Adeno-Associated Virus as a General Tradsduction Vector for Mammalian Cells,” Curr. Top. Microbiol. Immunol., 158, 97-129, 1992.Applicant
• Nambair et al., “Total Synthesis and Cloning of a Gene Coding for the Ribonuclease S. Protein,” Science 223, 1299-1301, 1984.Applicant
• Orkin, et al., “Report and Recommendations . . . ” (1995).Applicant
• Remington's Pharmaceutical Sciences 18th ed., Easton Pa: Mack Pub. Co., 1990.Applicant
• Rich et al., “Development and Analysis of Recombinant Adenoviruses for Gene Therapy of Cystic Fibrosis,” Human Gene Therapy, 4, 461-76, 1993.Applicant
• Rock, A new foreign policy: MHC molecules monitor the outside world, Immunol, Today 17, 131-37, 1995.Applicant
• Rodriguez, et al., “DNA Immunization with Minigenes: Low Frequency of Memory Cytotoxic T Lymphocytes and Inefficient Antiviral Protection Are Rectified by Ubiquitination,” J. Virol. 72:5174-5181 (1998).Applicant
• Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd ed., pp. 16.6-16.15, Cold Spring Harbor Laboratory Press, New York, 1989.Applicant
• Samulski et al., “Helper-Free Stocks of Recombinant Adeno-Associated Viruses, Normal Integration Does not Require Viral Gene Expression,” J. Virol., 63, 3822-28, 1989.Applicant
• Schlehofer et al., “Vaccinia Virus, Herpes Simplex Virus and Carcinogens Induce DNA Amplification in a Human Cell Line and Support Replication of A Helpervirus Dependent Parvovirus,” Virol., 152, 110-117, 1986.Applicant
• Schreiber et al., “Unique Tumor-Specific Antigens,” Ann. Rev. Immunol. 6, 465-83, 1988.Applicant
• Seth et al., “Mechanism of Enhancement of DNA Expression Consequent to Coininternalization of a Replication-Deficient Adenovirus and Unmodified Plasmid, DNA,” J. Virol. 68, 933-40, 1994.Applicant
• Shelling and Smith, “Targerted intergration of transfected and infected adeno-associated virus vectors containing the neomycin resistance gene,” Gene Therapy, 1, 165-69, 1994.Applicant
• Shigekawa et al., “Electroporation of Eukaryotes and Prokaryotes: A General Approach to the Indrocution of Macromolecules into Cells,” BioTech, 6, 742-51, 1988.Applicant
• Sikora, “Genetic Approaches to Cancer Therapy,” Gene Therapy, 1, 149-51, 1994.Applicant
• Spence et al., “Regulation of A bifunctional mRNA results in synthesis of secreted and nuclear probasin,” Proc. Natl. Acad. Sci., USA, 86,7843-47, 1989.Applicant
• Szomolanyi-Tsuda, et al., “T-Cell-Independent Immunoglobulin G Responses In Vivo Are Elicited by Live-Virus Infection but Not by Immunization with Viral Proteins or Virus-Like Particles,” J. Virol. 72:6665-6670 (1998).Applicant
• Thomson, et al., Human Herpesvirus 6 (HHV-6) is a Helper Virus for Adeno-Associated Virus Type 2 (AAV-2) and the AAV-2 rep Gene Homologue in HHV-6 Can Mediate AAV-2 DNA Replication and Regulate Gene Expression, Virol., 204, 304-11, 1994.Applicant
• Tratschin et al., Experientia vol. 42, 695 (1986).Applicant
• Tsuji et al., “Recombinant Sindbis Viruses Expressing a Cytotoxic T-Lymphocyte Epitope of a Malaria Parasite or of Influenza Virus Elicit Protection against the Corresponding Pathogen in Mice.” J. Virol., 72:6907-6910 (1998).Applicant
• Uetsuki et al., “Isolation and Characterzation of The Human Chromosomal Gene for Polypeptide Chain Elongation Factor-1a,” J. Biol. Chem., 264,5791-98, 1989.Applicant
• Ulmer, et al. “Protective CD4+ and CD8+ T Cells against Influenza Virus Induced by Vaccination with Nucleprotein DNA,” J. Virol., 72:5648-5653 (1998).Applicant
• Unanue et al., “The Basis for the Immunoregulatory Role of Macrophages and Other Accessory Cells,” Science 236, 551-557, 1987.Applicant
• Van Bruggen et. al, “Autoimmunity against nuclesomes and lupus nephritis,” Ann. Med. Interne (Paris), 147, 485-89, 1996.Applicant
• Verma et al., Science, vol. 389,239-242 (1997).Applicant
• Verma and Somia, “Gene Therapy-promises, problems, prospects,” Nature 389:239-242 (1997).Applicant
• Vincent et al., “Replication and Packaging of HIV Envelope Genes in a Novel Adeno-associated Virus Vector Syste,” Vaccines 90, 353-59, (Cold Spring Harbor Laboratory Press), 1990.Applicant
• Voss et al., “The role of enhancers in the regulation of cell-type-specific transcriptional control.” Trends Biochem Sci., 11, 287-89, 1986.Applicant
• Warshaw et al., “Pancreatic Carcinoma,” N. Engl. J. Med., 326, 455-465, 1992.Applicant
• Wu and Wallace, “The Ligation Amplification Reaction (LAR)-Amplification of Specific DNA Sequences Using Sequential Rounds of Template Dependent Ligation,” Geonomics, 4, 560-69, 1989.Applicant
• Xiao et al., Exp. Neurol. vol. 144, 113-124, (1997).Applicant
• Xiao et al., “Efficient Long-Term Gene Transfer Into Muscle Tissue of Immunocompetent Mice by Adeno-Associated Virus Vector,” J. Virol. 70, 8098-8108, 1996.Applicant
• Yang et al., “Immune Responses to Viral Antigens Versus Transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo,” Gene Therapy 3: 137-144 (1996).Applicant
• Yang et al., “Cellular Immunity to Viral Antigens Limits E1-deleted Adenoviruses for gene therapy,” Proc. Natl. Acad. Sci. 91: 4407-4411 (1994).Applicant
• Yauch, et al, “Role of Individual T-Cell Epitopes of Theiler's Virus in Pathogenesis of Demyelination Correlates with the Ability to Induce a Th1 Response,” J. Virol., 72: 6169-6174 (1998).Applicant
• Young et al., Adeno-Associated Virus—an Extreme State of Viral Defectiveness, Prog. Med. Virol., 25, 113-32, 1979.Applicant
• Zhou et al., “Adeno-associated Virus 2-mediated High Efficency Gene Transfer into Immature and Matrue Subsets of Hematopoietic Progenitor Cells In Human Umbilical Cord Blood,” J. Exp. Med., 179, 1867-75, 1994.Applicant
• Bonnet, et al., “Recombinant Viruses as a Tool for Therapeutic Vaccination against Human Cancers,” Immunology Letters 74 (2000) 11-25.Applicant
• Coulie, et al., “A Monoclonal Cytolytic T-lymphocyte Response Observed in a Melanoma Patient Vaccinated with a Tumor-Specific Antigenic Peptide Encoded by Gene MAGE-3,” PNAS, Aug. 28, 2001, vol. 98, No. 18, 10290-10295.Applicant
• Eder, et al., “A Phase I Trial of a Recombinant Vaccinia Virus Expressing Prostate-specific Antigen in Advanced Prostate Cancer,” Clinical Cancer Research, vol. 6, 1632-1638 (May 2000).Applicant
• Abstract of Khleif, et al., “A Phase I Vaccine Trial with Peptides Reflecting Ras Oncogene Mutations of Solid Tumors,” PubMed, J Immunother (Mar. 1999) 22(2): 155-65.Applicant
• Gulley, et al., “Phase I Study of a Vaccine Using Recombinant Vaccinia Virus Expressing PSA (rV-PSA) in Patients With Metastatic Androgen-Independent Prostate Cancer,” The Prostate (2002) 53: 109-117.Applicant
• Johnen, et al., “Long-term Tumor Growth Supression in Mice Immunized with Naked DNA of the Human Tumor Antigen Mucin (MUC1),” Cancer Immunol Immunother (2001) 50: 356-360.Applicant
• Ben-Hur, et al., “Tumor-Preventive Effects of the Soluble p53 Antigen on Chemically-Induced Skin Cancer in Mice,” Anticancer Research 18: 4237-4242 (1998).Applicant
• Berinstein, N., “Carcinoembryonic Antigen as a Target for Therapeutic Anticancer Vaccines: A Review,” Journal of Clinical Oncology, vol. 20, No. 8 (Apr. 15, 2000) 2197-2207.Applicant
• White, et al., “Induction of Anti-Tumor Immunity by Intrasplenic Administration of a Carcineombryonic Antigen DNA Vaccine,” The Journal of Gene Medicine, J Gene Med (2000) 2: 135-140.Applicant